With millions of cases of SARS-CoV-2 infection and nearly 350,000 deaths worldwide due to COVID-19 to date, the need for specific antiviral therapies is imperative. Multiple repurposed or newly developed antiviral treatments have been proposed. Many treatments for COVID-19 have been described in case series and retrospective cohort studies (May 8 FLARE), but few have been tested in a randomized controlled trial (May 11 FLARE). In tonight's FLARE, we review the publication of the Adaptive COVID-19 Treatment Trial-1 (ACTT-1), an RCT that resulted in the emergency use authorization by the U.S. Food and Drug Administration (FDA) for remdesivir (Beigel et al. 2020).